JPRN-UMIN000023579招募中未知
WT1 Trio Peptide-vaccine for Rare Cancers - WT1 Trio Peptide-vaccine for Rare Cancers
Osaka University Graduate School of Medicine Dept. Cancer Immunotherapy0 个研究点目标入组 90 人开始时间: 2016年9月10日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 16years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1 A patient with active infectious disease. 2 A patient with severe complication or complications. 3 A patient with severe mental disorder. 4 A patient who participates in any other clinical trial 5 A patient who should not be recruited to the clinical trial as determined by the investigators
研究者
相似试验
已完成
2 期
WT1 peptide-based cancer vaccine combined with gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a randomised, multicenter, phase 2 clinical studyPancreatic cancerJPRN-UMIN000005248Department of Cancer Immunotherapy, Osaka university Graduate school of Medicine150
尚未招募
2 期
WT1 peptide-based cancer vaccine in patients with high risk rhabdomyosarcoma, a multicenter, phase 2 clinical studyrhabdomyosarcomaJPRN-UMIN000013325Osaka university graduate school of medicine Pediatrics33
招募中
不适用
WT1 peptide-based cancer vaccine for long-term maintenance of anti-tumor immunitysolid tumor, malignant lymphoma, acute leukemiaJPRN-UMIN000015997Osaka University Graduate Shool of Medicine, Functional Diagnostic Science56
已完成
不适用
The novel therapeutic cancer peptide vaccine therapy for patients with locally advanced or metastatic pacreatic cancer combined with Gemcitabine as the first line therapy.-Phase I/II studypancreatic cancerJPRN-UMIN000014481Second Department of Surgery, Wakayama Medical University, School of Medicine10
招募中
不适用
A clinical study of WT1 peptide-based cancer vaccine WT1 Trio for myeloproliferative neoplasmsmyeloproliferative neoplasms (Polycythemia vera, Essential thrombocythemia,Essential thrombocytosis) MPN (PV, ET)JPRN-UMIN000031960Osaka university Graduate School of Medicine20